BC Innovations | Sep 18, 2019
Distillery Therapeutics

TAP inhibition for multiple cancers

DISEASE CATEGORY: Cancer INDICATION: B cell lymphoma; T cell lymphoma; breast cancer; pancreatic cancer Inhibiting TAP could treat B and T cell lymphoma, breast and pancreatic cancers. An siRNA targeting TAP conjugated to an oligonucleotide...
BC Innovations | Feb 21, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles DNA-based nucleolin-targeting nanoparticles could be used to deliver therapies for cancer. The nanoparticles consist of DNA tubes with an inner surface conjugated to therapeutic cargos and an outer surface linked to aptamers that...
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
BC Week In Review | Feb 16, 2015
Clinical News

IPP-204106: Phase I/IIa data

A dose-ranging, European Phase I/IIa trial showed that the MTD of IPP-204106 was 9 mg/kg when administered with chondroitin sulfate. ImmuPharma said it plans to start a Phase II trial of IPP-204106 to treat pancreatic...
BC Innovations | Nov 6, 2014
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Synthetic aptamer-polymer hybrid constructs for targeted drug delivery to tumor cells Aptamer-polymer hybrid constructs could be useful for selective delivery of chemotherapeutic agents to tumor...
BC Week In Review | Mar 18, 2013
Company News

Cylene Pharmaceuticals, TetraGene deal

Cylex granted TetraGene an option to acquire exclusive, worldwide rights to Cylene's associated anticancer quadruplex-targeting technologies, including Quarfloxin. Cylex will receive an undisclosed upfront fee and is eligible for milestones and royalties. Quarfloxin, which is...
BC Extra | Dec 12, 2012
Financial News

CharlestonPharma closes seed round

CharlestonPharma LLC (Charleston, S.C.) raised an undisclosed amount in a seed round led by new investor Sears Capital Management. Other undisclosed investors also participated. CharlestonPharma is developing human mAbs against nucleolin to treat cancer and...
BC Innovations | Nov 15, 2012
Distillery Techniques

Technology: Imaging

Approach Summary Licensing status Publication and contact information Imaging Imaging cancer metastasis using aptamer-functionalized silica nanoparticles Aptamer-functionalized silica nanoparticles could be used to image tumor metastasis. Silica nanoparticles with a diameter of 20 nm were...
BC Week In Review | Oct 8, 2012
Clinical News

IPP-204106: Phase I/II started

ImmuPharma began a dose-ranging, European Phase I/II trial to evaluate a new formulation of IPP-204106 in about 30 patients. The new formulation combines IPP-204106 with an excipient that forms micro/nano structures. ImmuPharma plc (LSE:IMM), London,...
BC Innovations | Aug 25, 2011
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Respiratory syncytial virus (RSV) Nucleolin In vitro and mouse studies suggest nucleolin inhibitors could help prevent RSV infection. A virus binding assay and mass...
Items per page:
1 - 10 of 63